<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>20 Primary bone sarcomas</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part25.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part27.htm">Далее &gt;</a></p><p style="padding-top: 4pt;padding-left: 49pt;text-indent: 0pt;text-align: left;"><a href="#bookmark26" class="s17" name="bookmark71">Chapter 20</a><a name="bookmark72">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 49pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="374" height="1" alt="image" src="Image_287.png"/></span></p><p style="padding-top: 4pt;padding-left: 49pt;text-indent: 0pt;text-align: left;"><a href="part5.htm#bookmark26" class="h2">Primary bone </a><h2 href="#bookmark26">sarcomas</h2></p><p class="s18" style="padding-top: 10pt;padding-left: 48pt;text-indent: 0pt;line-height: 111%;text-align: left;">Gulshad Begum, sarah prewett, Gail horan, and emma-Louise Gerety</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-top: 12pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">20.1 <span class="h4">Introduction</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Bone sarcomas are rare tumours, accounting for 0.2% of all new cancers in the UK. They are 8–10 times less common than soft tissue sarcomas but are often more chal- lenging to manage, with many presenting in teenagers and young adults.<span class="s22">1,2 </span>They occur more commonly in males than females (59% vs. 41%), and the majority occur in the lower limb (34%), followed by pelvis (17%), upper limb (12%), and head (12%). The most common presenting symptoms are non-mechanical bone pain (typically worse at night) and swelling. Functional impairment and spontaneous fractures are usually late presentations.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Primary bone sarcomas may be bone forming (osteogenic) or cartilage forming (chondrogenic). Osteosarcoma, Ewing’s sarcoma, and chondrosarcoma are the most common. Less common types include spindle cell sarcoma, notochordal tumours (chordoma), giant cell tumours of bone, vascular tumours (angiosarcoma), and adamantinomas.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Osteosarcoma is a primary mesenchymal tumour characterized histologically by osteoid-forming malignant cells. Incidence shows bimodal distribution, with a first peak at 10–20 years and second peak at 70–80 years. It is the most common bone tumour in adolescents and young adults but second most common in the older popu- lation. Osteosarcoma usually arises in the metaphysis of long bones, especially around the knee in children and adolescents. In elderly patients, the axial skeleton and cranio- facial bones may be involved and it is usually secondary to malignant degeneration in chronic disorders such as Paget’s disease, extensive bone infarcts, or post irradiation. There are eight different subtypes, some of which have characteristic imaging features such as parosteal and telangiectatic osteosarcoma.<span class="s22">3</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: right;">Ewing’s sarcoma of the bone is the second most common primary bone tumour in children and adolescents. Median age at diagnosis is 15 years. The commonest sites in order of frequency are pelvis, femur, tibia, fibula, rib, scapula, vertebra, and humerus.<span class="s22">4 </span>Chondrosarcomas are malignant cartilage-containing bone tumours, most fre- quently seen in adulthood at 30–60 years. They are the most common bone sarcoma in this age group, ahead of osteosarcomas. Common sites include pelvis and ribs (45%), ilium (20%), femur (15%), and humerus (10%). Secondary chondrosarcoma can arise due to malignant transformation of an osteochondroma, particularly in</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">patients with hereditary multiple exostoses. Imaging may be required to monitor po- tential malignant transformation of the cartilage cap, which is found to be at greater risk of chondrosarcoma if thicker than 2 cm. Chondrosarcomas may also arise in enchondromas in patients with Ollier’s or Maffucci syndrome.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Chordomas account for 8% of all primary bone tumours and arise from primitive notochordal remnants. Most common sites involved are pelvis, sacrum, vertebral column, face, and skull. They show a relatively indolent course with local destruction and extension into adjacent soft tissue.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Giant cell tumours (GCT) are rare, locally aggressive bone tumours with low malig- nant potential, accounting for about 5% of primary bone tumours. Peak incidence is at 20–45 years of age and most commonly these occur at the ends of long bones in the lower limb. Less than 5% of GCTs metastasize, typically to the lungs.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">All suspected cases of bone sarcoma should be discussed within a specialist multi- disciplinary team at a specialist centre. Management of bone tumours, especially osteosarcomas and Ewing’s sarcoma, involves intense and complex multi-modality treatments aiming for long-term disease control whilst minimizing late treatment toxicity.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">20.2 <span class="h4">Diagnosis and staging</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Radiology has a pivotal role in the diagnosis, staging, treatment, and follow-up of pa- tients with malignant bone tumours.<span class="s22">5 </span>The age of the patient and location of the tumour are characteristics that may help initially to formulate a differential diagnosis. A radio- graph is usually the first step in the diagnostic work-up, followed by cross-sectional imaging with MRI and/or CT and then nuclear medicine (Table 20.1).</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">20.2.1 <span class="s124">Radiographs</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Plain radiographs are usually the initial imaging modality in patients presenting with bone pain or swelling.<span class="s22">6 </span>Images are acquired in two planes, usually frontal and lateral. The precise location of the lesion is described in terms of the affected bone, whether located within the epiphysis, metaphysis, or diaphysis, and whether central, eccentric,</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-left: 50pt;text-indent: 0pt;line-height: 117%;text-align: left;">Table 20.1 <span class="s25">role of different imaging modalities in the diagnosis and staging of bone sarcomas</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 50pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="330" height="1" alt="image" src="Image_288.png"/></span></p><p class="s39" style="padding-bottom: 2pt;padding-left: 50pt;text-indent: 0pt;text-align: left;">Modality       Indication</p><p style="padding-left: 50pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="330" height="1" alt="image" src="Image_289.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="328" height="1" alt="image" src="Image_290.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="328" height="1" alt="image" src="Image_291.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-left: 50pt;text-indent: 0pt;line-height: 164%;text-align: left;">plain radiograph     First-line diagnosis; lung/bone metastases mri           second-line diagnosis</p><p class="s41" style="padding-bottom: 1pt;padding-left: 140pt;text-indent: -90pt;line-height: 112%;text-align: left;">Ct           diagnosis; surgical planning staging/follow-up</p><p style="padding-left: 50pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="330" height="1" alt="image" src="Image_292.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="328" height="1" alt="image" src="Image_293.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="328" height="1" alt="image" src="Image_294.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-left: 50pt;text-indent: 0pt;line-height: 164%;text-align: left;">[18F] FdG—pet/Ct    staging/follow-up Bone scintigraphy    Bone metastases</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">or cortically located. The lesion is described as lucent, dense, or heterogenous and the matrix calcification classified as ground glass, chondroid, or osteoid. The zone of transition is described, ranging from well-defined and geographic to diffuse and permeative. Cortical destruction, periosteal reaction, pathological fracture, soft tissue component, and multiplicity of the lesion is also assessed. Characteristics of non- aggressive and aggressive lesions are well described, with aggressive features including an indistinct margin, cortical expansion, and periosteal reaction.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Bone has a hard outer layer of dense cortex (up to 80% of adult bone mass) and an inner, less dense layer of cancellous, trabecular, or spongy bone. Osteoblastic bone lesions appear radio-dense due to increased bone deposition resulting in thickened coarse trabeculae. Osteolytic lesions show thinning of the trabeculae with ill-defined margins and appear lucent on radiographs.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Typical features of osteosarcoma which may be demonstrated on a radiograph (Figure 20.1a,b) include a wide zone of transition, cortical breach with soft tissue mass, fluffy or cloud-like osteoid matrix calcification, periosteal elevation with a ‘sun- burst’ appearance, and Codman’s triangle. Codman’s triangle represents an area of sub-periosteal bone formation due to tumour lifting off the underlying periosteum, and is usually, but not exclusively, found in osteosarcoma. Parosteal osteosarcomas arise from the outer layer of the periosteum and therefore appear pedunculated (Figure 20.1c).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Ewing’s sarcoma on radiographs usually demonstrates ill-defined, permeative, moth-eaten bone destruction. Lesions can be mixed lytic and sclerotic or purely lytic. A multilayered ‘onion-skin’ periosteal reaction is seen in about 50% of these tumours (Figure 20.1d). There is often a much more extensive soft tissue lesion which may also be demonstrated on the radiograph as an area of increased soft tissue density.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Chondrosarcomas show a characteristic pattern of chondroid calcification, classic- ally described as whorls and arcs with calcified cartilaginous areas (popcorn calcifica- tion) and fusiform cortical expansion (Figure 20.1e).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The location of the lesion within the bone may also provide clues as to the type of tumour. For example, giant cell tumours of bone classically extend to the articular surface in bones with a closed physis and appear as well-defined, eccentric lesions without a sclerotic margin (Figure 20.1f). Matrix calcification and reactive periosteal new bone formation is <i>not </i>seen in GCTs.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Bone destruction, new bone formation, periosteal reaction, and soft tissue mass are concerning radiographic features and require urgent investigation and referral to a bone sarcoma MDT.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Radiographs are also used to monitor progression of bone lesions and may also dem- onstrate pathological fracture. They are also used for follow-up after excision of bone lesions and may subsequently demonstrate metal surgical prostheses (Figure 20.2).</p><p class="s28" style="padding-top: 9pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">20.2.2 <span class="s124">Magnetic resonance imaging</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">MRI is used for further characterization of suspicious lesions identified on radiographs as it enables assessment of the bone marrow and soft tissues and is used to stage local disease.<span class="s22">7 </span>Normal bone marrow contains a high percentage of fat and demonstrates</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s128" style="padding-left: 17pt;text-indent: 0pt;text-align: left;">		</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s128" style="padding-left: 17pt;text-indent: 0pt;text-align: left;">		</p><p style="text-indent: 0pt;text-align: left;"><span><img width="170" height="177" alt="image" src="Image_295.gif"/></span></p><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(d)</p><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="130" height="177" alt="image" src="Image_296.gif"/></span></p><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(e)</p><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(e)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(e)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="105" height="177" alt="image" src="Image_297.gif"/></span></p><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(f)</p><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(f)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(f)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="195" height="198" alt="image" src="Image_298.gif"/></span></p><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(c)</p><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="101" height="198" alt="image" src="Image_299.gif"/></span></p><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(b)</p><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="109" height="198" alt="image" src="Image_300.gif"/></span></p><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(a)</p><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s127" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(a)</p><p class="s24" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 20.1 <span class="s25">radiographs demonstrating: (a) aggressive, lucent bone lesion in the proximal humerus, found to be an osteosarcoma in a 22-year-old female; (b) osteosarcoma of the tibia in a 35-year-old female; (c) exophytic, ossified lesion in the right proximal femur, found to be a parosteal osteosarcoma in a 63-year-old male; (d) subtle changes of periosteal elevation and cortical irregularity in a ewing’s sarcoma of the proximal femur in a 10-year-old female; (e) chondroid calcification of a left fourth rib chondrosarcoma in a 32-year-old female; (f) aggressive, lytic lesion extending to the articular surface of the distal tibia in an 18-year-old female, characteristic of a giant cell tumour of bone.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">high signal intensity on T1-weighted MRI sequences. Non-lipomatous infiltrative bone marrow lesions show low T1 signal, due to replacement of normal fatty marrow by malignant cells. On T2-weighted images, bone lesions are usually hyperintense due to high water content (Figure 20.3). Both water and fat return high signal on T2- weighted imaging so fat suppression should be used to remove the signal from the fat. High water signal may be due to intracellular water within a lesion or extracellular water such as in reactive oedema adjacent to the lesion.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Routine MRI to investigate a potential bone sarcoma should include acquisition of T1-weighted and T2-weighted, fat saturated images in two planes (Figure 20.4).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="269" alt="image" src="Image_301.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 20.2 <span class="s25">Follow-up frontal radiographs of a giant cell tumour of the distal femur in a 40-year-old male. (a) Lucent lesion in the centre of the femoral metaphysis, extending to the articular surface. (b). pathological fracture of the medial femoral condyle. (c) Long stem total knee replacement.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="415" height="240" alt="image" src="Image_302.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Fig. 20.3 <span class="s25">malignant giant cell tumour of the left distal tibia in an 18-year-old female.</span></p><p class="s25" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: justify;">(a) radiograph demonstrates a bubbly, lytic lesion extending to the articular surface of the distal tibia. (b) t1-weighted mri with loss of fatty marrow signal due to the lesion in the distal tibia. (c) t2-weighted fat saturated mri demonstrates high water-sensitive signal in the lesion.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="402" height="244" alt="image" src="Image_303.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 20.4 <span class="s25">standard mri sequences for characterization of an osteosarcoma in the tibia of a 35-year-old female. imaging in two planes, coronal (a, b) and axial (c, d) with</span></p><p class="s25" style="padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">t1-weighted (a, c) and t2-weighted fat saturated (b, d) sequences. Fluid-fluid levels are noted (arrow) in keeping with haemorrhage.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Post-contrast imaging with gadolinium is rarely necessary or useful for character- ization of bone lesions. However, it may in some cases help to distinguish the most vascularized part of tumour from necrotic areas and hence guide sites for successful biopsy. Post-gadolinium images are T1-weighted with fat suppression so that only gadolinium-enhanced tissues are of high signal. Recent studies have also found that the dynamic uptake of gadolinium by bone sarcomas may be able to predict chemo- therapy response.<span class="s22">8</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">MRI allows accurate assessment of the location and size of the lesion, its intramedullary extent, and any involvement of joints, muscle compartments, and neurovascular bundles. MRI also enables assessment of any soft tissue component, which may be particularly important for Ewing’s sarcoma and may not be well dem- onstrated on radiograph (Figure 20.5).</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Imaging of the affected area should include the whole of the involved bone and adjacent joints both superiorly and inferiorly, as this may identify skip lesions (Figure 20.6) and is vital for subsequent surgical planning.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Given the young age of many of the patients with osteosarcoma and Ewing’s sar- coma, MRI can be challenging as it may be a daunting and scary prospect for the child and their family. It is typically necessary to keep still for 3–4 minutes at a time for acquisition of each set of images. MRI play therapists may help facilitate the imaging but younger children may still need a general anaesthetic. MRI may also be difficult in some adults due to claustrophobia and anxiety, and may be contraindicated in the presence of certain metal implants and pacemakers.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s128" style="padding-left: 39pt;text-indent: 0pt;text-align: left;">	</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="170" height="136" alt="image" src="Image_304.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="166" height="136" alt="image" src="Image_305.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="166" height="136" alt="image" src="Image_306.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 20.5 <span class="s25">mri characterization of ewing’s sarcoma in the left ilium (arrow)—the soft tissue component is much more extensive than the osseous changes. (a) radiograph demonstrates density over the left ilium and subtle periosteal elevation. (b) t1-weighted mri with loss of fatty bone marrow signal in the left ilium. (c) t2-weighted fat saturated mri showing extensive high t2 signal in the soft tissue mass adjacent to the left ilium.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s28" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">20.2.3 <span class="s124">Computed tomography</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">CT is used for characterization of bone lesions when MRI is contraindicated, for image-guided bone biopsy, and for surgical planning. CT is more sensitive than MRI at demonstrating calcification, which appears black on standard MRI sequences. CT identifies areas of radiolucency, matrix calcification, and subtle cortical erosion and is better able to demonstrate bone structure. CT images are rapidly acquired in the axial plane in seconds and can then be reformatted into coronal and sagittal planes or any oblique plane as required. The axial images can also be reformatted into 3D recon- structions which may further aid surgical planning (Figure 20.7). Models may be 3D printed from the CT axial data to aid surgical planning and prosthesis design. CT also plays a vital role in the staging of tumours, and unenhanced CT of the chest is per- formed to look for metastatic lung disease.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">20.2.4 <span class="s124">Nuclear medicine</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Bone scintigraphy for the detection of skeletal metastases is standard in the current work-up of patients with primary bone tumours (Figure 20.8). Bone scintigraphy is relatively inexpensive, convenient, and visualizes the entire skeleton, including sites that are difficult to assess on radiographs, such as ribs, sternum, scapula, and sacrum. The radiotracer technetium–99m methylene diphosphonate (<span class="s22">99m</span>Tc-MDP) is imaged,</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="306" alt="image" src="Image_307.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 20.6 <span class="s25">tiny skip lesion in a 16-year-old male with left medial femoral condyle osteosarcoma. (a) Coronal t1-weighted mri. (b) Coronal t2-weighted fat saturated mri. Arrow: primary osteosarcoma. Arrowhead: tiny skip lesion.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="404" height="268" alt="image" src="Image_308.png"/></span></p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s54" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s54" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s54" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s54" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s54" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s54" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s54" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p class="s54" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s54" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p class="s24" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: justify;">Fig. 20.7 <span class="s25">Ct characterization of a chondrosarcoma (arrow) of the left fourth rib in a 38-year-old female. (a) radiograph. (b) unenhanced, thin axial Ct image. (c) sagittal reformatted Ct image. (d) Coronal reformatted image. (e) 3d reformatted image.</span></p><p class="s25" style="padding-left: 11pt;text-indent: 0pt;line-height: 10pt;text-align: justify;">(f) Virtual reality reformatted image.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s128" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">	</p><p style="text-indent: 0pt;text-align: left;"><span><img width="269" height="384" alt="image" src="Image_309.png"/></span></p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="142" height="380" alt="image" src="Image_310.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: justify;">Fig. 20.8 <span class="s25">Bone metastases demonstrated by 99 mtc-mdp bone scintigraphy (a, b) and mri (c, d) in a 12-year-old female with a ewing’s sarcoma in the right eighth rib.</span></p><p class="s25" style="padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: justify;">(a) Anterior bone scintigram. (b) posterior bone scintigram demonstrating uptake in the metabolically active physes as well as the primary rib ewing’s sarcoma (arrow) and bone metastases in the proximal tibiae and spine (arrowheads). (c) t1-weighted coronal mri.</p><p class="s25" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: justify;">(d) t2-weighted fat saturated coronal mri of the left knee demonstrate the metastases.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">which localizes to areas of new bone formation where it is taken up by active osteo- blasts. Once the radiotracer has been administered intravenously, the whole body can be imaged to localize the uptake of the tracer.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Bone scintigraphy may demonstrate increased uptake of <span class="s22">99m</span>Tc-MDP at the site of the primary tumour, in the adjacent bone (due to increased vascularity), in bone me- tastases, and in bone-forming metastases in soft tissues such as osteosarcoma lung metastases (Figure 20.9). Of note, benign conditions may also show increased uptake due to degenerative or inflammatory arthritis, trauma, and infection.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Positron emission tomography (PET)/CT or PET/MRI, are being used increasingly for staging purposes (including the detection of ‘skip’ bone lesions), and again allow the whole skeleton/body to be imaged.<span class="s22">9</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">18-fluoride labelled fluorodeoxyglucose (<span class="s22">18</span>F-FDG), the most commonly used PET tracer, is a glucose analogue that concentrates in areas of high metabolic activity.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="204" alt="image" src="Image_311.png"/></span></p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Fig. 20.9 <span class="s25">osteosarcoma pulmonary metastases may be positive on bone scintigraphy.</span></p><p class="s25" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">(a) 99 mtc-mdp uptake in an ossified pulmonary metastasis (arrow) in a 23-year-old female with previous tibial osteosarcoma. (b) Axial Ct image of ossified right lower lobe metastasis, right lower lobe collapse, and right pleural effusion.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Tumour cells show high metabolic activity with rapid cell division and an increased number of glucose transporters, therefore showing increased uptake. High uptake is also physiological in many organs, including myocardium, gastric mucosa, brain tissue, thyroid, and salivary glands, which limits evaluation of these areas. As <span class="s22">18</span>F-FDG is excreted within the urinary system, ‘normal’ uptake is also seen in the kidneys, col- lecting system, and bladder, which can obscure the detection of malignancy in these structures. PET images can be fused with CT or MRI images for accurate anatomical localization of tracer uptake.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">About one quarter of Ewing’s sarcoma patients present with metastases (40% of those are found in lung, 40% in bone/bone marrow). <span class="s22">18</span>F-FDG PET/CT may be suffi- cient for screening of bone and bone marrow metastases in Ewing’s sarcoma. PET may help characterize benign versus malignant pathology, detect occult metastatic disease, identify optimal sites for tissue sampling, and assess treatment response and recur- rence (Figure 20.10).<span class="s22">10 18</span>F-sodium fluoride (<span class="s22">18</span>F-NaF) is a radio-tracer that is taken up by metabolically active bone and is making a comeback as <span class="s22">18</span>F-NaF PET/CT has been found to have a higher sensitivity for bone metastases compared to 99mTc-MDP bone scintigraphy and <span class="s22">18</span>F-FDG-PET/CT. PET-CT and PET-MRI show future promise for the imaging of bone sarcomas; however, in many centres these modalities are not yet available in routine practice.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">20.3 <span class="h4">Interventional radiology</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Biopsy is required for histopathological confirmation of the diagnosis and to direct further treatment. Local imaging of the affected bone allows planning of the optimal site for biopsy. Contrast enhanced MRI can reveal the most vascularized parts of the tumour and MRI guidance minimizes the risk of a non-diagnostic yield by avoiding necrotic regions. The core bone biopsy is usually CT-guided (Figure 20.11a).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="420" height="359" alt="image" src="Image_312.png"/></span></p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s25" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: justify;"><span class="s24">Fig. 20.10 </span>An 18-year male with a sacral ewing’s sarcoma and left pleural (arrowhead) and lung (arrow) metastases demonstrated by <span class="s63">18</span>F-FdG pet/Ct. (a) Coronal <span class="s63">18</span>F-FdG pet with uptake in the left lung and pleura. (b) Fused axial <span class="s63">18</span>F-FdG pet/Ct. (c) Axial Ct.</p><p class="s25" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: justify;">(d) Axial <span class="s63">18</span>F-FdG pet.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Biopsy is ideally performed by a specialist sarcoma surgeon who will take into account possible future surgical approaches. This should minimize the risk of tumour spread to the skin or adjacent structures (biopsy tracts are marked with a small incision or tattoo to ensure that they are excised at the definitive procedure). Fine-needle biopsies are not suitable for primary diagnosis but can be used to confirm metastatic disease.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="142" alt="image" src="Image_313.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 20.11 <span class="s25">use of interventional radiology. (a) Ct-guided biopsy of a sacral lesion, found to be a chordoma on histopathology. (b, c) Fluoroscopically guided vertebroplasty to prevent sacral collapse and to relieve pain.</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Patients with spinal metastases may experience debilitating pain that significantly decreases their quality of life. Interventional radiology may aid with palliation by ver- tebral augmentation or radiofrequency ablation of spinal metastases.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Inoperable sacral chordomas are often treated with primary radiation and require high doses as they are relatively radio-resistant. One potential complication following radiation therapy to the pelvis is the risk of sacral insufficiency fractures in the weak- ened, irradiated bone. These can be incredibly painful, typically giving rise to lower back pain which may radiate down into the buttock or leg. Vertebroplasty can be per- formed to improve pain control and stabilize the vertebral bodies if standard analgesic measures are unsuccessful (Figure 20.11b,c).</p><p class="s19" style="padding-top: 9pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">20.4 <span class="h4">Response to treatment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">MRI of the primary tumour may be repeated to assess response to neo-adjuvant treat- ment. Response may not always be demonstrated by a clear reduction in size, indeed tumours may increase in size due to tissue necrosis which may be demonstrated by changes in enhancement pattern following intravenous gadolinium.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The goal of surgery is to safely remove the whole tumour with adequate tumour-free margins and attempt to salvage the limb where possible. Limb preservation involves removing the tumour and replacing the bone defect with a custom-made artificial prosthesis (see Figure 20.2).</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">MRI is essential prior to definitive surgical planning to assess the degree of intramedullary extension and invasion of the adjacent soft tissues.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Contraindications to limb conservation may include poor radiological response after neo-adjuvant chemotherapy and situations where a safe complete resection is not possible, such as in the presence of extensive soft tissue infiltration and/or invasion of neurovascular bundles. In children who are not yet fully grown, careful consideration is also required of the growth plate and whether this can be spared, to reduce the risk of limb length discrepancy in later life.</p><p class="s65" style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">18<span class="s44">F-FDG PET/CT may also be helpful in predicting histological response to neo- adjuvant therapy. Most malignant tumours have a maximum SUV&gt;2.5 while physio- logical uptake is usually &lt;2.5. Changes in SUV have prognostic value, and a 30% decrease or increase in SUV has been correlated with disease response to treatment or progression respectively.</span>9</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Radiographs and MRI are used for surveillance for local recurrence following cura- tive treatment. Baseline imaging should be obtained within 3–6 months of definite surgical resection using MRI. Recommended imaging follow-up intervals vary ac- cording to whether the tumour is deemed to be low or high risk.<span class="s22">11</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Gadolinium is useful for distinguishing between post-surgical inflammation, infec- tion, scarring, and recurrence. Metal prostheses may severely limit sensitivity of MRI for recurrence as the metal causes signal artefact due to distortion of the magnetic field. Metal artefact reduction sequences are possible but still may not be as sensitive in the adjacent area around the prosthesis.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Bone scintigraphy and PET/CT or PET/MRI where available, may also play a role in follow-up of primary bone sarcomas. They can be helpful in the detection of recur- rence and may be of value if there is diagnostic uncertainty with other cross-sectional imaging modalities (see Figure 20.10).</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">With the development of novel therapeutic agents such as tyrosine kinase inhibitors and specific immunotherapies, it is becoming increasingly important to have sensitive and specific imaging for the monitoring of disease response which may induce meta- bolic changes before structural changes occur.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">20.5 <span class="h4">Summary</span></p><p class="s23" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Primary bone sarcomas require a multidisciplinary approach to their management.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Appropriate imaging and the correct interpretation of this imaging is integral in the decision-making processes throughout the stages of treatment.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">As novel therapeutic drugs are developed, sensitive and specific follow-up imaging is essential for monitoring response to treatment.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s126" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">References</p><p class="s74" style="padding-top: 6pt;padding-left: 20pt;text-indent: -9pt;text-align: left;">1. <b>Gerrand C</b>, <b>Athanasou N</b>, <b>Brennan B, et al. </b>(2016). UK guidelines for the management of bone sarcomas. <i>Clinical Sarcoma Research</i>, <b>6</b>: 7.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -9pt;text-align: left;">2. <b>Casali PG</b>, <b>Bielack S</b>, <b>Abecassis N, et al. </b>(2018). Bone sarcomas: ESMO–PaedCan– EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i>, <b>29</b>(Suppl 4): iv79–95.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -9pt;text-align: left;">3. <b>Jarmish G</b>, <b>Klein MJ</b>, <b>Landa J</b>, <b>Lefkowitz FA</b>, <b>Hwang S </b>(2010). Imaging characteristics of primary osteosarcoma: nonconventional subtypes. <i>RadioGraphics</i>, <b>30</b>: 1653–1672.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -9pt;text-align: justify;">4. <b>Weber MA</b>, <b>Papakonstantinou O</b>, <b>Nikodinovska VV</b>, <b>Vanhoenacker FM </b>(2019). Ewing’s sarcoma and primary osseous lymphoma: spectrum of imaging appearances. <i>Seminars in Musculoskeletal Radiology</i>, <b>23</b>(1): 36–57.</p><p class="s74" style="padding-top: 1pt;padding-left: 10pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">5. <b>Kaste SC </b>(2016). Imaging pediatric bone sarcomas. <i>Radiology Clinics of North America</i>,</p><p class="s75" style="padding-left: 20pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">49<span class="s74">(4): 749–765.</span></p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -9pt;text-align: left;">6. <b>Colleen M</b>, <b>Costelloe</b>, <b>Madewell JE </b>(2013). Radiography in the initial diagnosis of primary bone tumors. <i>American Journal of Roentgenology</i>, <b>200</b>: 3–7.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -9pt;text-align: left;">7. <b>Nascimento D</b>, <b>Suchard G</b>, <b>Hatem M</b>, <b>de Abreu A </b>(2014). The role of magnetic resonance imaging in the evaluation of bone tumours and tumour-like lesions. <i>Insights Imaging</i>, <b>5</b>(4): 419–440.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -9pt;text-align: justify;">8. <b>Amit P</b>, <b>Patro DK</b>, <b>Basu D</b>, <b>Elangovan S</b>, <b>Parathasarathy V </b>(2014). Role of dynamic MRI and clinical assessment in predicting histologic response to neoadjuvant chemotherapy in bone sarcomas. <i>American Journal of Clinical Oncology</i>, <b>37</b>(4): 384–390.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -9pt;text-align: left;">9. <b>Behzadi AH</b>, <b>Raza SI</b>, <b>Carrino JA, et al. </b>(2018). Applications of PET/CT and PET/MR imaging in primary bone malignancies. <i>PET Clinics</i>, <b>13</b>(4): 623–624.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">10. <b>Newman EN</b>, <b>Jones RL</b>, <b>Hawkins DS </b>(2013). An evaluation of [F-18]-fluorodeoxy-D- glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma. <i>Pediatric Blood Cancer</i>, <b>60</b>(7): 1113–1117.</p><p class="s74" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;line-height: 11pt;text-align: left;">11. <b>Robers CC</b>, <b>Kransdorf MJ</b>, <b>Beaman FD, et al. </b>(2016). ACR appropriateness</p><p class="s74" style="padding-left: 20pt;text-indent: 0pt;text-align: left;">criteria: follow-up of malignant or aggressive musculoskeletal tumors. <i>Journal of American College of Radiologists</i>, <b>13</b>(4): 389–400.</p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part25.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part27.htm">Далее &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
